Multiple Endocrine Neoplasia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major multiple endocrine neoplasia markets are expected to exhibit a CAGR of 10.2% during 2024-2034.
The multiple endocrine neoplasia market has been comprehensively analyzed in IMARC's new report titled "Multiple Endocrine Neoplasia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Multiple endocrine neoplasia (MEN) refers to a rare genetic disorder characterized by the production of tumors in multiple endocrine glands. These tumors are typically benign but can lead to excessive hormone production, causing a range of symptoms and complications. The indications of the illness can vary depending on the affected glands but commonly include hyperparathyroidism, which causes elevated calcium levels and can result in kidney stones and weakened bones. Additionally, individuals suffering from MEN may experience symptoms related to the overproduction of hormones by the pituitary, adrenal, and pancreatic glands, such as excessive thirst, high blood pressure, and gastrointestinal issues. Diagnosing this ailment involves a multi-step process, including clinical evaluation and biochemical tests. Physicians may recommend genetic testing to identify mutations in the MEN1 or MEN2 genes, as well as imaging studies like CT scans or MRIs to locate tumors within the endocrine glands. Early detection and management of the disorder are crucial to prevent complications in patients.
The increasing cases of mutations in specific genes that help to regulate cell proliferation and division are primarily driving the multiple endocrine neoplasia market. In addition to this, the inflating utilization of potent pharmaceutical agents, such as somatostatin analogs, kinase inhibitors, and mTOR inhibitors, aimed at managing hormonal imbalances and inhibiting tumor growth, is also creating a positive outlook for the market. Moreover, the widespread adoption of radiation therapies, which focus on shrinking tumor sizes or relieving symptoms in individuals suffering from the ailment, is further bolstering the market growth. Apart from this, the rising usage of novel diagnostic modalities like advanced imaging techniques and molecular testing, since they can enhance early detection and accurate diagnosis, thereby facilitating timely and effective treatment, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of surgical interventions, including minimally invasive parathyroidectomy and laparoscopic adrenalectomy, that help to provide curative options with minimum side effects is also augmenting the market growth. Furthermore, the escalating application of gene therapy, which aims to replace or repair the faulty genes that lead to the development of tumors, is expected to drive the multiple endocrine neoplasia market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the multiple endocrine neoplasia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for multiple endocrine neoplasia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the multiple endocrine neoplasia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the multiple endocrine neoplasia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the multiple endocrine neoplasia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current multiple endocrine neoplasia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the multiple endocrine neoplasia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the multiple endocrine neoplasia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the multiple endocrine neoplasia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of multiple endocrine neoplasia across the seven major markets?
What is the number of prevalent cases (2018-2034) of multiple endocrine neoplasia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of multiple endocrine neoplasia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with multiple endocrine neoplasia across the seven major markets?
What is the size of the multiple endocrine neoplasia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of multiple endocrine neoplasia?
What will be the growth rate of patients across the seven major markets?
Multiple Endocrine Neoplasia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for multiple endocrine neoplasia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the multiple endocrine neoplasia market?
What are the key regulatory events related to the multiple endocrine neoplasia market?
What is the structure of clinical trial landscape by status related to the multiple endocrine neoplasia market?
What is the structure of clinical trial landscape by phase related to the multiple endocrine neoplasia market?
What is the structure of clinical trial landscape by route of administration related to the multiple endocrine neoplasia market?
The multiple endocrine neoplasia market has been comprehensively analyzed in IMARC's new report titled "Multiple Endocrine Neoplasia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Multiple endocrine neoplasia (MEN) refers to a rare genetic disorder characterized by the production of tumors in multiple endocrine glands. These tumors are typically benign but can lead to excessive hormone production, causing a range of symptoms and complications. The indications of the illness can vary depending on the affected glands but commonly include hyperparathyroidism, which causes elevated calcium levels and can result in kidney stones and weakened bones. Additionally, individuals suffering from MEN may experience symptoms related to the overproduction of hormones by the pituitary, adrenal, and pancreatic glands, such as excessive thirst, high blood pressure, and gastrointestinal issues. Diagnosing this ailment involves a multi-step process, including clinical evaluation and biochemical tests. Physicians may recommend genetic testing to identify mutations in the MEN1 or MEN2 genes, as well as imaging studies like CT scans or MRIs to locate tumors within the endocrine glands. Early detection and management of the disorder are crucial to prevent complications in patients.
The increasing cases of mutations in specific genes that help to regulate cell proliferation and division are primarily driving the multiple endocrine neoplasia market. In addition to this, the inflating utilization of potent pharmaceutical agents, such as somatostatin analogs, kinase inhibitors, and mTOR inhibitors, aimed at managing hormonal imbalances and inhibiting tumor growth, is also creating a positive outlook for the market. Moreover, the widespread adoption of radiation therapies, which focus on shrinking tumor sizes or relieving symptoms in individuals suffering from the ailment, is further bolstering the market growth. Apart from this, the rising usage of novel diagnostic modalities like advanced imaging techniques and molecular testing, since they can enhance early detection and accurate diagnosis, thereby facilitating timely and effective treatment, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of surgical interventions, including minimally invasive parathyroidectomy and laparoscopic adrenalectomy, that help to provide curative options with minimum side effects is also augmenting the market growth. Furthermore, the escalating application of gene therapy, which aims to replace or repair the faulty genes that lead to the development of tumors, is expected to drive the multiple endocrine neoplasia market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the multiple endocrine neoplasia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for multiple endocrine neoplasia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the multiple endocrine neoplasia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the multiple endocrine neoplasia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the multiple endocrine neoplasia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current multiple endocrine neoplasia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the multiple endocrine neoplasia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the multiple endocrine neoplasia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the multiple endocrine neoplasia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of multiple endocrine neoplasia across the seven major markets?
What is the number of prevalent cases (2018-2034) of multiple endocrine neoplasia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of multiple endocrine neoplasia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with multiple endocrine neoplasia across the seven major markets?
What is the size of the multiple endocrine neoplasia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of multiple endocrine neoplasia?
What will be the growth rate of patients across the seven major markets?
Multiple Endocrine Neoplasia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for multiple endocrine neoplasia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the multiple endocrine neoplasia market?
What are the key regulatory events related to the multiple endocrine neoplasia market?
What is the structure of clinical trial landscape by status related to the multiple endocrine neoplasia market?
What is the structure of clinical trial landscape by phase related to the multiple endocrine neoplasia market?
What is the structure of clinical trial landscape by route of administration related to the multiple endocrine neoplasia market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MULTIPLE ENDOCRINE NEOPLASIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MULTIPLE ENDOCRINE NEOPLASIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MULTIPLE ENDOCRINE NEOPLASIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 MULTIPLE ENDOCRINE NEOPLASIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MULTIPLE ENDOCRINE NEOPLASIA - UNMET NEEDS
10 MULTIPLE ENDOCRINE NEOPLASIA - KEY ENDPOINTS OF TREATMENT
11 MULTIPLE ENDOCRINE NEOPLASIA - MARKETED PRODUCTS
11.1 List of Multiple Endocrine Neoplasia Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 MULTIPLE ENDOCRINE NEOPLASIA - PIPELINE DRUGS
12.1 List of Multiple Endocrine Neoplasia Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. MULTIPLE ENDOCRINE NEOPLASIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. MULTIPLE ENDOCRINE NEOPLASIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MULTIPLE ENDOCRINE NEOPLASIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Multiple Endocrine Neoplasia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Multiple Endocrine Neoplasia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Multiple Endocrine Neoplasia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Multiple Endocrine Neoplasia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Multiple Endocrine Neoplasia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Multiple Endocrine Neoplasia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Multiple Endocrine Neoplasia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Multiple Endocrine Neoplasia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Multiple Endocrine Neoplasia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Multiple Endocrine Neoplasia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Multiple Endocrine Neoplasia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Multiple Endocrine Neoplasia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Multiple Endocrine Neoplasia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Multiple Endocrine Neoplasia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Multiple Endocrine Neoplasia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Multiple Endocrine Neoplasia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Multiple Endocrine Neoplasia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Multiple Endocrine Neoplasia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Multiple Endocrine Neoplasia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Multiple Endocrine Neoplasia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Multiple Endocrine Neoplasia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Multiple Endocrine Neoplasia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Multiple Endocrine Neoplasia - Access and Reimbursement Overview
16 MULTIPLE ENDOCRINE NEOPLASIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MULTIPLE ENDOCRINE NEOPLASIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MULTIPLE ENDOCRINE NEOPLASIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MULTIPLE ENDOCRINE NEOPLASIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MULTIPLE ENDOCRINE NEOPLASIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MULTIPLE ENDOCRINE NEOPLASIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 MULTIPLE ENDOCRINE NEOPLASIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MULTIPLE ENDOCRINE NEOPLASIA - UNMET NEEDS
10 MULTIPLE ENDOCRINE NEOPLASIA - KEY ENDPOINTS OF TREATMENT
11 MULTIPLE ENDOCRINE NEOPLASIA - MARKETED PRODUCTS
11.1 List of Multiple Endocrine Neoplasia Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 MULTIPLE ENDOCRINE NEOPLASIA - PIPELINE DRUGS
12.1 List of Multiple Endocrine Neoplasia Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. MULTIPLE ENDOCRINE NEOPLASIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. MULTIPLE ENDOCRINE NEOPLASIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MULTIPLE ENDOCRINE NEOPLASIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Multiple Endocrine Neoplasia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Multiple Endocrine Neoplasia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Multiple Endocrine Neoplasia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Multiple Endocrine Neoplasia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Multiple Endocrine Neoplasia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Multiple Endocrine Neoplasia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Multiple Endocrine Neoplasia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Multiple Endocrine Neoplasia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Multiple Endocrine Neoplasia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Multiple Endocrine Neoplasia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Multiple Endocrine Neoplasia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Multiple Endocrine Neoplasia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Multiple Endocrine Neoplasia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Multiple Endocrine Neoplasia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Multiple Endocrine Neoplasia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Multiple Endocrine Neoplasia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Multiple Endocrine Neoplasia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Multiple Endocrine Neoplasia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Multiple Endocrine Neoplasia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Multiple Endocrine Neoplasia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Multiple Endocrine Neoplasia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Multiple Endocrine Neoplasia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Multiple Endocrine Neoplasia - Access and Reimbursement Overview
16 MULTIPLE ENDOCRINE NEOPLASIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MULTIPLE ENDOCRINE NEOPLASIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MULTIPLE ENDOCRINE NEOPLASIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
